Targeted Therapies for Brain Tumors: Will They Ever Deliver?
- PMID: 29798907
- DOI: 10.1158/1078-0432.CCR-18-0855
Targeted Therapies for Brain Tumors: Will They Ever Deliver?
Abstract
The strategy of using biologically targeted therapeutics for cancer has yet to translate into effective treatment of gliomas. The neuro-oncology community is beginning to recognize that phase 0 studies should be performed to account for the impact of the blood-brain barrier on the ability of a therapeutic to reach its target(s). Clin Cancer Res; 24(16); 3790-1. ©2018 AACRSee related article by Sanai et al., p. 3820.
©2018 American Association for Cancer Research.
Comment on
-
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.Clin Cancer Res. 2018 Aug 15;24(16):3820-3828. doi: 10.1158/1078-0432.CCR-17-3348. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798906 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
